Sharp Therapeutics Corp.
SHRX.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 344.23% | -18.50% | -37.18% | 52.96% | -19.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 117.00% | 31.12% | 22.96% | 41.79% | 12.41% |
| Operating Income | -117.00% | -31.12% | -22.96% | -41.79% | -12.41% |
| Income Before Tax | -89.36% | 28.52% | 40.57% | -33.23% | 8.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -89.36% | 28.52% | 40.57% | -33.23% | 8.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -89.36% | 28.52% | 40.57% | -33.23% | 8.91% |
| EBIT | -117.00% | -31.12% | -22.96% | -41.79% | -12.41% |
| EBITDA | -121.61% | -33.38% | -25.60% | -46.96% | -14.07% |
| EPS Basic | 99.18% | 99.55% | 77.45% | -17.98% | -114.38% |
| Normalized Basic EPS | 98.99% | 99.40% | 70.80% | -27.39% | -96.65% |
| EPS Diluted | 99.18% | 99.55% | 77.45% | -17.98% | -114.38% |
| Normalized Diluted EPS | 98.99% | 99.40% | 70.80% | -27.39% | -96.65% |
| Average Basic Shares Outstanding | 221.35% | 1,276.47% | 438.60% | 268.70% | 107.12% |
| Average Diluted Shares Outstanding | 221.35% | 1,276.47% | 438.60% | 268.70% | 107.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |